Fabrizio Bonanni Net Worth

The estimated Net Worth of Fabrizio Bonanni is at least $27.8 Milion dollars as of 27 July 2012. Fabrizio Bonanni owns over 315,148 units of XBiotech Inc stock worth over $313,737 and over the last 21 years Fabrizio sold XBIT stock worth over $27,497,645.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fabrizio Bonanni XBIT stock SEC Form 4 insiders trading

Fabrizio has made over 6 trades of the XBiotech Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Fabrizio sold 315,148 units of XBIT stock worth $25,911,469 on 27 July 2012.

The largest trade Fabrizio's ever made was selling 315,148 units of XBiotech Inc stock on 27 July 2012 worth over $25,911,469. On average, Fabrizio trades about 10,201 units every 82 days since 2003. As of 27 July 2012 Fabrizio still owns at least 48,491 units of XBiotech Inc stock.

You can see the complete history of Fabrizio Bonanni stock trades at the bottom of the page.

What's Fabrizio Bonanni's mailing address?

Fabrizio's mailing address filed with the SEC is , , , , .

Insiders trading at XBiotech Inc

Over the last 9 years, insiders at XBiotech Inc have traded over $50,443,920 worth of XBiotech Inc stock and bought 1,428,502 units worth $11,921,113 . The most active insiders traders include Street Financial S.A. Bay, Fondation Rennes a W Thorpe Mckenzie. On average, XBiotech Inc executives and independent directors trade stock every 48 days with the average trade being worth of $1,053,782. The most recent stock trade was executed by W Thorpe Mckenzie on 16 December 2021, trading 250,000 units of XBIT stock currently worth $2,500,000.

What does XBiotech Inc do?

xbiotech is developing a first-in-class monoclonal antibody (mabp1) to inhibit chronic inflammation. chronic (sterile) inflammatory responses are involved in the progression of many serious and common diseases. mabp1 is being investigated in many important areas of medicine, including: cancer, leukemia (phase 1); type 2 diabetes (phase2); psoriasis (phase 2); and vascular disease (phase 2). mabp1 is a true human™ antibody cloned from a natural human immune response and—unlike currently marketed antibodies—it has not undergone any modification to alter its function. it has exhibited the best potential tolerability and safety during the clinical trials. xbiotech has established a current good manufacturing practices (cgmp) program to commercialize its lead product candidate. the company has purchased land and designed a commercial-scale plant with 25,000l total bioreactor capacity. construction of the facility is planned to commence in 4th quarter 2011..

Complete history of Fabrizio Bonanni stock trades at AMGEN a XBiotech Inc

XBiotech Inc executives and stock owners

XBiotech Inc executives and other stock owners filed with the SEC include:

• John Simard,
  Chairman of the Board, President, Chief Executive Officer, Founder
• John Simard,
  Founder, Pres, CEO & Chairman
• Sushma Shivaswamy,
  Chief Scientific Officer
• Queena Han,
  Vice President - Finance and Human Resources, Secretary
• Dr. Sushma Shivaswamy,
  Chief Scientific Officer
• Queena Han CPA, B.A., CPA, C.G.A.,
  VP of Fin. & HR and Sec.
• W. Thorpe McKenzie,
  Independent Director
• Donald MacAdam,
  Independent Director
• Peter Libby,
  Independent Director
• Jan-Paul Waldin,
  Lead Independent Director
• Lisa Simard,
  Director of Corp. Strategy - XBiotech USA, Inc.
• Benjamín Guzmán,
  Sr. VP of Corp. Strategy & Fin.
• Daniel Vasella,
  Director
• Trey Benson,
  VP of Commercial Development
• Kelly Thornburg,
  SVP of Operations
• Fabrizio Bonanni,
  Director
• Dawn Mc Collough,
  VP Clinical Operations
• Michael Stecher,
  Medical Director
• Kalidip Choudhury,
  VP of Business Development
• James Scott Whitehurst,
  Chief Financial Officer
• Thomas Gut,
  10% owner
• Benjamin Guzman,
  Sr.VP Corp. Strategy & Finance
• Fondation Rennes,
  10% owner
• Street Financial S.A. Bay,
  10% owner